Severe hypertriglyceridaemia during treatment with capecitabine

Evaluation of lipid profiles in patients treated with capecitabine

“…It is well known that capecitabine is converted by thymidine phosphorylase to 5-FU. Because a previous study investigating the effect of 5-FU on serum lipid levels showed a significant reduction in total cholesterol in both patients and animals, hypertriglyceridemia may be attributed either to capecitabine itself or to precursor of 5-FU (5)(6)(7)(11)(12)(13)(14)(15)(16). The second is related to a lipoprotein lipase (LPL) defect.…”

“…The second is related to a lipoprotein lipase (LPL) defect. A defect of LPL is linked with an accumulation of chylomicrons and/or of very low-density lipoprotein (VLDL) (6,7,10,(12)(13)(14)(15)(16). Kurt et al suggest that CIHT may appear more readily in individuals with hereditary LPL deficiency (14).…”

“…It is worth noting that LPL defect also occurs in the case of an increase in its inhibitor (apolipoprotein CIII) and/or a decrease in its activator (apolipoprotein CII). However, the link between capecitabine and apolipoprotein CII/CIII levels has never been explored (6,7,10,(12)(13)(14)(15)(16). The third is capecitabine causes pancreatic inflammation and this inflammation causes hyperglycemia and hypertriglyceridemia (5,10,12,13).…”

Capecitabine-Induced Hypertriglyceridemia and Hyperglycemia: Two Cases

“…A study investigating the effect of 5-FU on plasma lipid levels in patients and in animals showed a significant reduction of the total plasma cholestero and a decrease in TG levels in animals [8]. Although cholesterol constitutes a prodrug of 5-FU, recent reports suggest an influence on lipid metabolism through different pathways and that capecitabine may cause HTG [2,3,[7][8][9][10]. Table 2 shows the reports about the capecitabine-associated dyslipidemia [2,3,7,[9][10][11][12][13][14].…”

“…Although cholesterol constitutes a prodrug of 5-FU, recent reports suggest an influence on lipid metabolism through different pathways and that capecitabine may cause HTG [2,3,[7][8][9][10]. Table 2 shows the reports about the capecitabine-associated dyslipidemia [2,3,7,[9][10][11][12][13][14]. When we looked at the literature findings, we found disruptions in the lipid profile, especially in TG, in 4 cases with breast cancer and in 12 with colorectal cancer [2,3,7,[9][10][11][12][13].…”